Recovery & RepairGrade B
KPV
An alpha-MSH-derived tripeptide (Lys-Pro-Val) studied for anti-inflammatory effects, particularly in gut and skin models.
- Regulatory status
- Not approved
- Half-life
- Short (minutes to hours)
- Route
- Subcutaneous, oral, or topical
- Evidence
- Limited human trials or approved outside the US
Mechanism of action
Inhibits NF-kB and pro-inflammatory cytokine transcription intracellularly.
Studied and reported uses
- Inflammatory bowel conditions
- Topical skin inflammation
Dosing information
Reported research use200–500 mcg daily
Oral/gutEnteric capsules used for colonic delivery
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Side effects
- Well tolerated in reports
- Unknown long-term profile
Research evidence
Colitis models
Reduced inflammation markers in mice.